PROK · PROKIDNEY CORP.

NasdaqHealthcareBiotechnology

Prokidney Corp Is A Clinical-Stage Biotechnology Company Pioneering The Development Of A First-In-Class, Autologous Cell Therapy That Is Intended To Preserve Kidney Function In Patients With Advance Chronic Kidney Disease (Ckd) And Diabetes. Its Product Candidate, React (Renal Autologous Cell Therapy), Is A Disease-Modifying Cell Therapy Made From A Patient'S Renal Cells. React Has The Potential To Slow And Stabilize The Progression Of Chronic Kidney Disease. The Company'S Pipeline Consists Of The Development Program For Severe Diabetic Kidney Disease.

HealthcareNasdaqUS

$4.92

+695.3% latest move

Price & move as of the most recent catalyst (Jul 7) — not a live quote.

FLOAT

89.7M

FREE FLOAT %

43%

SHARES O/S

208.9M

MARKET CAP

$348.9M

EXCHANGE

Nasdaq

COUNTRY

PROK Catalyst History

Other and Special SituationsJul 7, 2025 · 7:38pm ET

PROKPROKIDNEY CORP.

ProKidney Corp. Reports Positive Phase 2 Trial Results for Rilparencel in CKD Patients

Topline results show statistically and clinically significant outcomes.

Be early on the next PROK spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →